Loading…
Apimeds Pharmaceuticals US, Inc. is projected to decline to $3.97 by 2027, a -18% move from its current price of $4.85. APUS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $4.43 | $4.85 | $5.31 | -0.02% |
| Aug 6 | $4.27 | $4.85 | $5.51 | -0.04% |
| Aug 7 | $4.14 | $4.85 | $5.67 | -0.07% |
| Aug 8 | $4.04 | $4.85 | $5.81 | -0.09% |
| Aug 9 | $3.96 | $4.84 | $5.93 | -0.11% |
| Aug 10 | $3.88 | $4.84 | $6.04 | -0.13% |
| Aug 11 | $3.81 | $4.84 | $6.15 | -0.16% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.81 | $4.84 | $6.15 | -0.16% |
| Week 2 | $3.45 | $4.83 | $6.78 | -0.31% |
| Week 3 | $3.19 | $4.83 | $7.31 | -0.47% |
| Week 4 | $2.99 | $4.82 | $7.78 | -0.62% |
| Week 5 | $2.82 | $4.81 | $8.22 | -0.78% |
| Week 6 | $2.67 | $4.80 | $8.63 | -0.94% |
| Week 7 | $2.55 | $4.80 | $9.03 | -1.09% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc. It is categorized in Healthcare.
APUS is the asset with a current price of $4.92. It has a market cap of $7.42M and is ranked 4890 by market value. The near-term picture is neutral, while the long-term forecast spans through 2050 with a wide range of potential outcomes.
The forecast shows movement from 2026 to 2050, starting at a neutral level in 2026 (avg $4.92) and turning bullish later, with 2050 projected to average $17.45 and a max of $40.14. Notable mid-term milestones include 2029 avg $6.27 (ROI 27.5, sentiment BULLISH) and 2030 avg $6.00 (ROI 21.9, BULLISH). The path carries some downside risk in earlier years but substantial upside in the long run.
A major floor 86.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.4% away) — a key level to hold.
The nearest ceiling, 124.7% above — a clean break opens room to run.
A major ceiling 260.8% above — clearing it would confirm fresh momentum.
Key APUS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of APUS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.02 | Sell | $5.46 | Sell |
| MA 10 | $5.02 | Sell | $4.85 | Buy |
| MA 20 | $2.87 | Buy | $3.67 | Buy |
| MA 50 | $1.87 | Buy | $2.88 | Buy |
| MA 100 | $3.63 | Buy | $4.71 | Buy |
| MA 200 | $11.38 | Sell | $8.80 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.18 | Neutral |
| Stoch RSI (14) | 52.07 | Neutral |
| CCI (20) | 58.59 | Neutral |
| Williams %R (14) | -38.71 | Info |
| MACD (12,26,9) | 0.34 | Buy |
| ROC (12) | 627.40 | Buy |
| Bollinger %B (20,2) | 0.71 | Neutral |
| Stochastic %K (14) | 61.29 | Neutral |
| TRIX (15) | 9.22 | Buy |
| Awesome (5,34) | 3.91 | Buy |
| Ultimate (7,14,28) | 51.00 | Neutral |
| Momentum (10) | 4.49 | Buy |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 5.83 | Sell |
| ADX (14) | 44.29 | Buy |
| ATR (14) | 0.67 | Info |
Technical sentiment is NEUTRAL. The RSI14 stands at 30, suggesting a mix of sellers and buyers in the near term. The SMA50 is $10.11 and the SMA200 is $16.52, indicating price moving averages above the current level.
Support is at $4.92 and resistance at $13.10. The 30-day price range runs from $2.67 to $9.06, highlighting near-term volatility alongside a wide longer-term forecast.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.85 | $4.85 | $6.65 | 0% | Neutral | |
| $2.80 | $3.97 | $6.09 | -18% | Bearish | |
| $2.90 | $4.42 | $7.30 | -9% | Neutral | |
| $3.80 | $6.17 | $10.76 | +27% | Bullish | |
| $3.46 | $5.96 | $10.85 | +23% | Bullish | |
| $3.53 | $6.43 | $12.17 | +32% | Bullish | |
| $3.41 | $6.55 | $12.83 | +35% | Bullish | |
| $2.58 | $5.22 | $10.54 | +8% | Neutral | |
| $2.45 | $5.22 | $10.83 | +8% | Neutral | |
| $2.63 | $5.85 | $12.45 | +21% | Bullish | |
| $3.49 | $7.75 | $17.82 | +60% | Bullish | |
| $7.75 | $17.22 | $39.60 | +255% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $4.85 | $4.85 | $6.45 | +0.00% |
| September 2026 | $4.21 | $5.16 | $6.64 | +6.49% |
| October 2026 | $3.81 | $4.75 | $6.25 | -7.99% |
| November 2026 | $3.73 | $4.71 | $6.31 | -0.89% |
| December 2026 | $3.82 | $4.89 | $6.65 | +3.73% |
Click any year to see its month-by-month APUS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Apimeds Pharmaceuticals US, Inc.'s 2026 outlook centres on $4.85, within a $4.85 to $6.65 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, APUS could reach as high as $6.09, with a base case around $3.97 and support toward $2.80 — roughly -18% from $4.85. Expect choppier, lower action through this leg of the cycle.
Expect APUS to range from $2.90 to $7.30 through 2028. The $4.42 average target implies a -9% move from current prices. That is up +12% on the projected 2027 average. Price action looks broadly range-bound.
The APUS price prediction for 2029 points to an average of $6.17 (low $3.80, high $10.76) — a potential gain of +27% on today's $4.85. Buyers look set to stay in control over this stretch.
In 2030, APUS is projected to trade between $3.46 and $10.85, averaging $5.96 — a potential gain of +23% from today's $4.85. That is -4% versus the projected 2029 average. Momentum favours further upside here.
Apimeds Pharmaceuticals US, Inc.'s 2031 outlook centres on $6.43, within a $3.53 to $12.17 range. That is up +8% on the projected 2030 average. That marks a +32% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, APUS could reach as high as $12.83, with a base case around $6.55 and support toward $3.41 — roughly +35% from $4.85. Momentum favours further upside here.
Expect APUS to range from $2.58 to $10.54 through 2033. The $5.22 average target implies a +8% move from current prices. That is -20% versus the projected 2032 average. A consolidation phase looks the most probable path here.
The APUS price prediction for 2034 points to an average of $5.22 (low $2.45, high $10.83) — a potential gain of +8% on today's $4.85. Price action looks broadly range-bound.
In 2035, APUS is projected to trade between $2.63 and $12.45, averaging $5.85 — a potential gain of +21% from today's $4.85. That is up +12% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Apimeds Pharmaceuticals US, Inc.'s 2040 outlook centres on $7.75, within a $3.49 to $17.82 range. That is up +32% on the projected 2035 average. That marks a +60% change versus current levels. Momentum favours further upside here.
By 2050, APUS could reach as high as $39.60, with a base case around $17.22 and support toward $7.75 — roughly +255% from $4.85. Buyers look set to stay in control over this stretch.
Investing $1,000 in APUS today (≈ 206.185567 APUS) could be worth
$3,549.6
+$2,549.6 (+255%) by 2050 · US Dollar
Based on the average projected APUS price of $17.22 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in APUSwould be worth at today's price.
$1,000 invested in APUS on Jul 31, 2025 (≈ 57.471266 APUS) would be worth
$278.74
-$721.26 (-72.1%) today · 0.28× · US Dollar
Based on a APUS entry price of $17.4 vs. today's $4.85.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.65 | $858.41 | -14.2% |
| 1 month ago | $0.885 | $5,480.23 | +448.0% |
| 3 months ago | $1.88 | $2,579.79 | +158.0% |
| 6 months ago | $17.8 | $272.47 | -72.8% |
| 1 year ago | $17.4 | $278.74 | -72.1% |
| All time (1.2y) ago | $22 | $220.45 | -78.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our APUS forecast.
Our base-case forecast reaches $9.70 around 2050.
Implied market cap at $9.70: $14.64M
The multi-year forecast outlines a rise in average prices from 2026 through 2050. In 2029 the average is $6.27 with ROI 27.5 and sentiment BULLISH, followed by 2030 with avg $6.00 and ROI 21.9 (BULLISH). By 2031 the average is $6.56 (ROI 33.4) and 2032 shows $6.66 (ROI 35.4), both BULLISH.
The forecast remains broadly bullish into the 2030s, with 2033 at $5.22 (ROI 6) and 2034 at $5.34 (ROI 8.6).
Looking ahead to 2040, the average price is projected to $7.95 (ROI 61.6, BULLISH), and in 2050 the average climbs to $17.45 (ROI 254.7, BULLISH) with a max forecast of $40.14. The path includes years with lower momentum and occasional bearish signals, underscoring the uncertain and probabilistic nature of price forecasting.
Tap a question to reveal the answer.
In 2030 the forecast shows min $3.48, avg $6.00, max $10.95 with ROI 21.9 and sentiment BULLISH.
The forecast maximum is $40.14 in 2050, with an avg of $17.45 and min $7.85, ROI 254.7 and sentiment BULLISH.
Annualized volatility is 200.
Current price is $4.92 and market cap is $7.42M.
The 30-day range is $2.67 to $9.06.
Apimeds Pharmaceuticals US, Inc. Community Discussion
0Share your Apimeds Pharmaceuticals US, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.